Cargando…

Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity

The CD20-directed monoclonal antibody rituximab (RTX) established a new era in the treatment of non-Hodgkin lymphoma (NHL); however, suboptimal response and/or resistance to RTX still limit its clinical merits. Although four effector mechanisms are validated to participate in CD20-based immunotherap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hua-Fei, Wu, Cong, Chen, Ting, Zhang, Ge, Zhao, He, Ke, Chang-Hong, Xu, Zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525799/ https://www.ncbi.nlm.nih.gov/pubmed/26257518 http://dx.doi.org/10.2147/IJN.S80129

Ejemplares similares

Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster
por: Li, Huafei, et al.
Publicado: (2015)

Magnetic Properties of Ni-doped ZnO Nanocombs by CVD Approach
por: ShaoMin, Zhou, et al.
Publicado: (2010)

Complement system in Anti-CD20 mAb therapy for cancer: A mini-review
por: Gao, Yiwen
Publicado: (2023)

SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023)

Ultra-High Sensitivity Zinc Oxide Nanocombs for On-Chip Room Temperature Carbon Monoxide Sensing
por: Pan, Xiaofang, et al.
Publicado: (2015)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

IL‐2mAb reduces demyelination after focal cerebral ischemia by suppressing CD8(+) T cells
por: Zhou, Yu‐Xi, et al.
Publicado: (2018)

The Different Colors of mAbs in Solution
por: Ambrogelly, Alexandre
Publicado: (2021)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Characterization of Two Novel mAbs Recognizing Different Epitopes on CD43
por: Kim, Soseul, et al.
Publicado: (2014)

Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with (90)Y or (177)Lu
por: Karczmarczyk, Urszula, et al.
Publicado: (2022)

B cell depletion with anti-CD20 mAb exacerbates anti-donor CD4(+) T cell responses in highly sensitized transplant recipients
por: Tanaka, Asuka, et al.
Publicado: (2021)

Cellular tools for biosimilar mAb analysis
por: Lindemann, Carsten, et al.
Publicado: (2013)

Evolving trends in mAb production processes
por: Shukla, Abhinav A., et al.
Publicado: (2017)

State of the art in anti-cancer mAbs
por: Chiavenna, S. M., et al.
Publicado: (2017)

M.A.B. Economy: Its Excellent Results
Publicado: (1917)

LPS combined with CD47mAb enhances the anti‑osteosarcoma ability of macrophages
por: Yuan, Peng, et al.
Publicado: (2023)

A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb
por: Wu, Yang, et al.
Publicado: (2021)

Stability enhancement in a mAb and Fab coformulation
por: Zhang, Hongyu, et al.
Publicado: (2020)

Pan-sarbecovirus mAb protects from variants
por: Flemming, Alexandra
Publicado: (2021)

A mAb for the detection of the antiretroviral drug emtricitabine
por: Youngpairoj, Ae S., et al.
Publicado: (2022)

Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
por: Zhang, Jingzhe, et al.
Publicado: (2019)

Doxorubicin-loaded platelets conjugated with anti-CD22 mAbs: a novel targeted delivery system for lymphoma treatment with cardiopulmonary avoidance
por: Xu, Peipei, et al.
Publicado: (2017)

IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells
por: Yu, Jifeng, et al.
Publicado: (2022)

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
por: Bolaños-Mateo, Elixabet, et al.
Publicado: (2014)

Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma
por: Mohanty, Suchismita, et al.
Publicado: (2019)

Novel strategy for a high-yielding mAb-producing CHO strain (overexpression of non-coding RNA enhanced proliferation and improved mAb yield)
por: Tabuchi, Hisahiro
Publicado: (2013)

The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent
por: He, Li-Zhen, et al.
Publicado: (2015)

Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs
por: Capuano, Cristina, et al.
Publicado: (2021)

Bispecific mAb(2) Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab
por: Stadlbauer, Katharina, et al.
Publicado: (2022)

Anti-CD137 mAb Deletes Both Donor CD4(+) and CD8(+) T Cells in Acute Graft-versus-host Disease
por: Kim, Juyang, et al.
Publicado: (2011)

Developmental changes in heparan sulfate expression: in situ detection with mAbs
Publicado: (1992)

Direct analysis of mAb aggregates in mammalian cell culture supernatant
por: Paul, Albert J, et al.
Publicado: (2014)

Conservancy of mAb Epitopes in Ebolavirus Glycoproteins of Previous and 2014 Outbreaks
por: Ponomarenko, Julia, et al.
Publicado: (2014)

Self-Interaction Chromatography of mAbs: Accurate Measurement of Dead Volumes
por: Hedberg, S. H. M., et al.
Publicado: (2015)

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
por: Kroesen, Michiel, et al.
Publicado: (2016)

Germinality does not necessarily define mAb expression and thermal stability
por: Schwaigerlehner, Linda, et al.
Publicado: (2019)

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
por: Golay, Josée, et al.
Publicado: (2020)

Combination therapies augment the anti-tumor activity of agonist CD27 mAb in human CD27 transgenic mouse models
por: He, Li-Zhen, et al.
Publicado: (2013)

Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity
por: Yu, Tao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pl0q01eb6euf4ah9m1f4dh6b63